Top Highlights for March 2014: (Please click on read more to see details)
- Indian pharma expected to cross US $27 billion by 2016: Deloitte Read more
- 2013 - India bags 15 M&A deals worth $1.7 billion in pharma, medical, and biotech industry.
- Hospira, US to acquire Indian Orchid API for US$200 million Read more
- Mylan Pharma enters India's critical care segment Read more
- Lupin enters Latin American market by Acquiring Specialty Ophthalmic Company in Mexico
- India, Russia partner for joint research in biotechnology Read more
- India, Japan establish lab to promote research in Life sciences
- India Australia to start joint research in priority areas of biotechnology under IABF Read more
- Germany's University, Indian Polyclone Company collaborate for a joint research project
For more such news and updates on Global Life Science Business in Indiaplease join this group at LinkedIn
Featured Opportunities and Aagami Updates: (Please click on link to view details)
1. Product Licensing opportunities:
- Elores– to combat antimicrobial resistance – Looking for partner to Launch in the US. Already launched in India and partnership completed for South Africa and South Korea.
- Partnership sought for low cost, stable, safe, malaria cure which overcomes drug resistance and is ready for human clinical trials
- Co-Development/Partnership opportunity in Oncology and STEMI mAbs with an Innate Immune Drug Development Company of Western Europe
- Co-development Opportunity with a US company in innovative Breast cancer vaccine and Prostate cancer vaccine
- Opportunity to Partner on new linker technology which combines Paclitaxel/ Doxorubicin/ Docetaxel with Albumin and make better generic of these drugs which can easily take the 505(b)2 pathway and will be patent protected.
2. Technology Licensing available for:
3. India Amazing Facts and Figures: A report presenting interesting facts on India's LifeScience Industry and the country's economy in general